Literature DB >> 22105536

Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory.

Jonathan K Nambiar1, Rachel Pinto, Juan I Aguilo, Kiyoshi Takatsu, Carlos Martin, Warwick J Britton, James A Triccas.   

Abstract

Definition of protective immunity induced by effective vaccines is important for the design of new pathogen control strategies. Inactivation of the PhoP response-regulator in Mycobacterium tuberculosis results in a highly attenuated strain that demonstrates impressive protective efficacy in pre-clinical models of tuberculosis. In this report we demonstrate that the protection afforded by the M. tuberculosis phoP mutant strain is associated with the long-term maintenance of CD4(+) T-cell memory. Immunization of mice with SO2 resulted in enhanced expansion of M. tuberculosis-specific CD4(+) T cells compared with vaccination with the BCG vaccine, with an increased frequency of these cells persisting at extended time-points after vaccination. Strikingly, vaccination with SO2 resulted in sustained generation of CD4(+) T cells displaying a central memory phenotype, a property not shared by BCG. Further, SO2 vaccination markedly improved the generation of polyfunctional cytokine-secreting CD4(+) T cells compared with BCG vaccination. The improved generation of functionally competent memory T cells by SO2 correlated with augmented recall responses in SO2-vaccinated animals after challenge with virulent M. tuberculosis. This study defines a mechanism for the protective effect of the SO2 vaccine and suggests that deletion of defined virulence networks may provide vaccine strains with potent immuno-stimulatory properties.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105536     DOI: 10.1002/eji.201141903

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

2.  A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosis.

Authors:  Liqin Wang; Miao Xu; Noel Southall; Wei Zheng; Shuishu Wang
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

Review 3.  Novel vaccine approaches for protection against intracellular pathogens.

Authors:  Kristin L Griffiths; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2014-03-06       Impact factor: 7.486

Review 4.  Protection versus pathology in tuberculosis: recent insights.

Authors:  Andrea M Cooper; Egidio Torrado
Journal:  Curr Opin Immunol       Date:  2012-05-19       Impact factor: 7.486

Review 5.  Vaccine development for tuberculosis: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 6.  The mycobacterial cell envelope-lipids.

Authors:  Mary Jackson
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-07       Impact factor: 6.915

Review 7.  The cell envelope glycoconjugates of Mycobacterium tuberculosis.

Authors:  Shiva Kumar Angala; Juan Manuel Belardinelli; Emilie Huc-Claustre; William H Wheat; Mary Jackson
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-06-10       Impact factor: 8.250

Review 8.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

Review 9.  Current status of new tuberculosis vaccine in children.

Authors:  Yu Pang; Aihua Zhao; Chad Cohen; Wanli Kang; Jie Lu; Guozhi Wang; Yanlin Zhao; Suhua Zheng
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

10.  Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.

Authors:  Adriana Aporta; Ainhoa Arbues; Juan I Aguilo; Marta Monzon; Juan J Badiola; Alba de Martino; Nadia Ferrer; Dessislava Marinova; Alberto Anel; Carlos Martin; Julian Pardo
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.